OpenEvidence, a platform often compared by healthcare professionals to ChatGPT but tailored for the medical field, is set to reveal a $200 million funding round at a $6 billion valuation, according to The New York Times.
This latest investment arrives just three months after the company secured $210 million at a $3.5 billion valuation, highlighting the strong investor enthusiasm for AI solutions designed for specific industries.
OpenEvidence’s system, which is trained on resources such as JAMA and the New England Journal of Medicine, enables users to swiftly access established medical information to assist in patient care. Licensed healthcare providers can use the ad-supported platform at no cost.
Since its launch in 2022, OpenEvidence has experienced rapid expansion. The Times notes that monthly clinical queries have almost doubled to 15 million since July.
Google Ventures led the funding round, with additional backing from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft.
TechCrunch has contacted OpenEvidence for a statement.